Efficacy of Topical 5% Acyclovir-1% Hydrocortisone Cream (ME-609) for Treatment of Herpes Labialis: a systematic review

Rosa, Maria Inês da; Souza, Suéli L; Farias, Bruna F De; Pires, Patrícia Duarte Simões; Dondossola, Eduardo Ronconi; Reis, Maria Eduarda Fernandes dos

doi:10.1590/0001-3765201520140701

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In herpes labialis, the results suggest that acyclovir 5% compounded with hydrocortisone 1% cream (ME-609) has a significant effect in reducing oral ulcer development and support earlier systematic review by Rosa et al [106] demonstrating a beneficial effect of early episodic treatment with the combination of an antiviral and corticosteroid. Combined antiviral and corticosteroid therapy may have additive effects.…”

Section: Discussionsupporting

confidence: 72%

Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis

Margono¹,

Sufiawati²

2020

SDS

View full text Add to dashboard Cite

Aim: To assess the evidence of the efficacy and safety of compounded topical medications in oral medicine cases. Methods: Electronic databases were searched from inception to October 2019 for studies that evaluated compounded topical medications in oral medicine cases to assess their efficacy and safety. Search terms included drug compounding, topical administration, clinical efficacy, and oral lesions. Only randomized controlled trials (RCTs) or cross-over trials of compounded topical drug versus non-compounded drug or placebo or standard treatment were included. The exclusion criteria included compounded topical medications with herbal ingredients in the intervention group to compare with the non-compounded drug. The primary outcome measure was a clinical resolution of the oral lesions. The secondary outcome measure was pain resolution. Adverse events of interventions were discussed. The quality of RCTs was assessed using the Cochrane risk of bias tool (RoB 2.0). The data were synthesised in a fixed-effect model using RevMan 5. The evidence across studies for an outcome and decision of recommendations was assessed using GRADE criteria for the subgroup of included studies selected in meta-analysis. Results: Of 90 studies, 27 studies were included in the meta-analysis. Overall, only 8% of included studies were assessed as being at low risk of bias. The compounded topical preparation of antiviral with corticosteroids appeared to be effective for reducing oral ulcers but not pain resolution in herpes labialis. The use clobetasol propionate 0.05% in mucoadhesive base for oral lichen planus, pilocarpine HCl 5 mg lozenge for radiation-induced xerostomia in head and neck cancer patients, amlexanox 5% in mucoadhesive base and doxycycline hyclate 100 mg in denture adhesive base for recurrent aphthous stomatitis, and morphine 0.2% mouthwash in controlling oral Conclusion: Some compounded topical medications may be effective for the treatment of oral medicine cases. Future well-designed studies using standardised measures are needed to provide high-quality evidence in evaluating the efficacy and safety of compounded topical medications for the management of oral mucosal diseases.

show abstract

Section: Discussionsupporting

confidence: 72%

Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis

Margono¹,

Sufiawati²

2020

SDS

View full text Add to dashboard Cite

show abstract

“…They reviewed five placebocontrolled and two comparative studies and concluded that treatment with oral antivirals decreased the lesion duration by about 1 day with modest clinical implication. Rosa et al 37 published a systematic review on 5% acyclovir-1% hydrocortisone cream compared to placebo for herpes labialis treatment. Their meta-analysis showed that early treatment with 5% acyclovir-1% hydrocortisone was beneficial.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review on the Efficacy of Topical Acyclovir, Penciclovir, and Docosanol for the Treatment of Herpes Simplex Labialis

Hammer

Dietz

et al. 2018

EMJ Dermatol

View full text Add to dashboard Cite

Background: Herpes simplex labialis is a common skin condition caused by the herpes simplex virus. The prescription of antivirals for the treatment of herpes labialis is common. The objective of this study was to conduct a systematic review of the available evidence on the treatment of herpes simplex labialis with U.S. Food and Drug Administration (FDA)-approved topical antibiotics. Methods: The literature search included searches of PubMed, Google Scholar, and Scopus. This review included studies that examined herpes labialis lesions and treatment with topical acyclovir, penciclovir, or docosanol in at least one of the study arms. Results: Of the 1,485 papers initially identified, 20 papers representing 19 randomised controlled trials and one quasi-randomised trial met the inclusion criteria for the systematic review. Conclusion: Our systematic review of the clinical studies performed on the three topical antiherpetics, acyclovir, penciclovir, and docosanol, showed that their efficacy compared to placebo is marginal at best (shortening the duration of pain by <24 hours), although the three topical antiherpetic drugs have no serious adverse reactions and are safe to use.

show abstract

“…Several stimuli can trigger HSV reactivation, such as ultraviolet radiation, abnormal hormone levels, fatigue, stress and traumatic events, as well as immunosuppression [ 1 , 10 ]. The development of herpes labialis and genital herpes lesions is sequential and begins with a prodrome showing erythema (usually accompanied by itching) [ 1 , 2 , 11 ], then papules, vesicles, ulcers or soft crust, hard crust, residual abnormalities (dry flaking skin and residual swelling and erythema), and finally reepithelization and healing (normal skin) [ 11 ]. Although HSV infections are usually benign [ 7 ], this virus can also cause severe diseases such as encephalitis, lymphocytic meningitis, blindness, and systemic disease in neonates and immunocompromised patients [ 7 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, the development of new antiviral agents has gained much interest in recent years [ 10 , 15 , 17 , 18 ]. Several natural products have shown antiviral effects against HSV, such as extracts, fractionated compounds, and isolated molecules obtained from plants, among others [ 1 , 11 , 15 , 18 ]. Furthermore, many plant-derived extracts have been reported to inhibit HSV replication [ 1 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex Mucocutaneous Infections and the Prevention of Recurrences: A Pilot Study

Kituashvili

Kvirkvelia

Galdava

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Background. Previous in vitro and in vivo studies indicated that walnut extract has a therapeutic effect on herpes simplex infections. This study aimed to evaluate the efficacy and tolerance of Lazolex® Gel (Iveriapharma, Tbilisi, Georgia), an emollient gel to treat mucocutaneous lesions caused by herpes simplex virus. Methods. A single-center, single-arm, open-label, phase II clinical trial was conducted with 30 patients divided into two groups: 15 patients with herpes simplex virus type 1 (HSV-1) infections and 15 with herpes simplex virus type 2 (HSV-2). All received topical treatment with Lazolex® Gel four times a day for 10 days. The efficacy and tolerance of the treatment were evaluated on day 10 and day 20 of the study. Recurrence rates were also evaluated both prior to treatment with Lazolex® and over a 4-year follow-up period subsequent to treatment. Results. The median effective time to resolution of symptoms (itching, burning, and pain) was 1.97 days in the HSV-1 group and 3.11 days in the HSV-2 group. The median effective time for vesicles and erosion to disappear was 3.64 days in the HSV-1 group and 3.88 days for the HSV-2 group. Finally, the median effective time for inflammatory signs to disappear was 5.70 and 4.32 days, respectively. Following treatment with Lazolex® Gel, the frequency of outbreaks decreased from a median of 2.00 and 1.00 times per year in the HSV-1 and HSV-2 cohorts to 0.25 and 0.00 ( p = 0.001 and p = 0.003 ), respectively. Conclusions. Topical treatment with Lazolex® Gel applied to lesions four times a day for 10 days was shown to be effective and safe in the treatment of herpes simplex mucocutaneous infections and dramatically reduced the rate of recurrence. Clinical trial was approved by Drug Agency of Ministry of Labour, Health and Social Affairs of Georgia, registration # DA Nº CT-000032, date of approval 01.10.2007.

show abstract

Efficacy of Topical 5% Acyclovir-1% Hydrocortisone Cream (ME-609) for Treatment of Herpes Labialis: a systematic review

Cited by 8 publications

References 14 publications

Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis

Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis

A Systematic Review on the Efficacy of Topical Acyclovir, Penciclovir, and Docosanol for the Treatment of Herpes Simplex Labialis

Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex Mucocutaneous Infections and the Prevention of Recurrences: A Pilot Study

Contact Info

Product

Resources

About